Handelsbanken Fonder AB Lowers Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Handelsbanken Fonder AB cut its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 16.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 24,400 shares of the company’s stock after selling 4,700 shares during the quarter. Handelsbanken Fonder AB’s holdings in CRISPR Therapeutics were worth $960,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of the business. Private Advisor Group LLC grew its holdings in shares of CRISPR Therapeutics by 18.5% in the fourth quarter. Private Advisor Group LLC now owns 85,036 shares of the company’s stock valued at $3,347,000 after acquiring an additional 13,289 shares in the last quarter. State of New Jersey Common Pension Fund D grew its holdings in shares of CRISPR Therapeutics by 10.8% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 44,692 shares of the company’s stock valued at $1,759,000 after acquiring an additional 4,351 shares in the last quarter. Allworth Financial LP grew its holdings in shares of CRISPR Therapeutics by 2,117.4% in the fourth quarter. Allworth Financial LP now owns 15,078 shares of the company’s stock valued at $593,000 after acquiring an additional 14,398 shares in the last quarter. Congress Asset Management Co. grew its holdings in shares of CRISPR Therapeutics by 4.5% in the fourth quarter. Congress Asset Management Co. now owns 68,739 shares of the company’s stock valued at $2,706,000 after acquiring an additional 2,971 shares in the last quarter. Finally, Van ECK Associates Corp grew its holdings in shares of CRISPR Therapeutics by 5,269.3% in the fourth quarter. Van ECK Associates Corp now owns 83,010 shares of the company’s stock valued at $3,267,000 after acquiring an additional 81,464 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Trading Down 1.8 %

CRSP opened at $43.62 on Friday. The company has a market cap of $3.74 billion, a P/E ratio of -9.98 and a beta of 1.67. CRISPR Therapeutics AG has a 12 month low of $36.52 and a 12 month high of $90.62. The business’s 50-day moving average price is $42.36 and its 200-day moving average price is $45.99.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. TD Cowen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a report on Wednesday, February 12th. Chardan Capital reduced their price objective on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a report on Thursday, February 13th. The Goldman Sachs Group reduced their price objective on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Evercore ISI raised CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $60.00 to $99.00 in a report on Friday, February 14th. Finally, HC Wainwright reissued a “buy” rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $74.40.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.